Table 3.
Summary of adverse events during triple antiplatelet therapy(significant effects are in bold).
| Patients | Intervention | Major bleeding | Minor bleeding | Blood transfusions | Thrombocytopenia | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Triple events/total |
Control events/total |
OR *(95% CI) | Triple events/total |
Control events/total |
OR* (95% CI) | Triple events/total |
Control events /total |
OR* (95% CI) | Triple events/total |
Control events/total |
OR* (95% CI) | ||
| NSTE-ACS | GP IIb/IIIa | 34/1275 | 30/1274 | 1.15 (0.69-1.91) | 46/1113 | 34/1111 | 1.37 (0.81-2.33) | 45/1174 | 36/1173 | 1.27 (0.81-2.00) | 8/1012 | 0/1010 | 17.1 (0.99-296.69) |
| STEMI | GP IIb/IIIa | 11/255 | 2/195 | 1.86 (0.43-8.17) | 23/255 | 7/195 | 2.73 (1.15-6.46) | 10/281 | 15/272 | 0.63 (0.28-1.44) | 11/238 | 4/181 | 1.51 (0.48-4.71) |
| Cilostazol | 0/30 | 0/30 | |||||||||||
| Elective PCI | GP IIb/IIIa | 42/3314 | 34/3309 | 1.29 (0.70-2.36) | 99/3314 | 62/3309 | 1.60 (1.16-2.21) | 71/3264 | 40/3263 | 1.79 (1.14-2.79) | 17/2269 | 0/2250 | 8.04 (1.82-35.59) |
| Cilostazol | 0/1054 | 1/1058 | 0.33 (0.01-8.24) | 6/1054 | 7/1058 | 0.85(0.28-2.56) | 1/450 | 2/450 | 0.62 (0.08-5.09) | ||||
| Clopidogrel | 1/60 | 0/60 | 3.10 (0.12-79.29) | 1/60 | 0/60 | 3.10 (0.12-79.23) | |||||||
*Odds ratios were calculated from random effect models.
NSTE-ACS, non-ST elevation acute coronary syndromes; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.